

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The paragraph on page 4 line 27:

-- In a more preferred embodiment the antagonist of the present invention comprises the amino acid sequence Xaa₁-Xaa₂-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH₂ (SEQ ID NO: 1), wherein Xaa₁ is a neutral amino acid, and Xaa₂ is a changed amino acid. --

The paragraph on page 12 line 29:

-- Figure 1:

Comparison of the amino acid sequence of human/rat corticotropin-releasing factor (h/rCRF) (SEQ ID NO: 2) with ovine corticotropin-releasing factor (oCRF) (SEQ ID NO: 3), rat urocortin (rUcn) (SEQ ID NO: 4), sauvagine (Svg) (SEQ ID NO: 5), and astressin (SEQ ID NO: 6). Identical amino acids are shaded. --

IN THE CLAIMS:

Claim 3(amended).

--The antagonist of claim 2 comprising the amino acid sequence Xaa₁-Xaa₂-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH₂ (SEQ ID NO: 1),

Docket No. 0147-0221P

wherein Xaa_1 is a neutral amino acid, and Xaa_2 is a charged amino acid. --